A magnetic bead-based immunoassay quantifies up to 100 biomarkers per sample.

More than a dozen vaccines for tuberculosis are currently being tested in clinical trials. Some use whole bacteria as BCG does, while others deliver protein subunits or genetic material carried by viral vectors.  

This month marks the 100-year anniversary of BCG, still the only approved vaccine against the lethal pathogen. But there are new vaccines for this wily foe on the horizon.

Scientists are on the hunt for a shot that will protect against not only SARS-CoV-2, but other members of its family that may emerge in the future.

Researchers at Imperial College London and the University of Oxford are exposing healthy volunteers to SARS-CoV-2 for science.

Some of the blood specimens collected in the United States for the NIH’s All of Us research program starting on January 2, 2020, have antibodies against SARS-CoV-2.

Tiny but powerful nanobodies may be the innovation that snuffs out the pandemic.

By avoiding the production of antibodies, something vaccines ordinarily induce, the immunization sidesteps the problem of antibody-dependent enhancement, which can amplify infection by a similar virus and is known to occur with dengue and Zika.

Vaccines against various forms of cancer prime the immune system to attack.

Nicholas Hutchings will discuss how recombinant antibody technology can speed up the response to a pandemic.

In the armpit lymph nodes of people who had received the mRNA vaccine against SARS-CoV-2, researchers found germinal centers needed to generate long-lived antibody-making cells.

Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.

Researchers find key drivers of allograft rejection!

A trio of papers shows that specialized antibodies can direct T cells to destroy cells that display portions of mutant cancer-related proteins, as well as T cells that have become cancerous themselves.

The decision adds to evidence that the benefits of plasma infusions from COVID-19 survivors may be limited, but advocates say the case isn’t closed.

Sam Wilson discusses a user-friendly set of resources that he and his collaborators developed to aid labs pivoting to study COVID-19.

A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.

In this workshop, Craig Pow will explore optimizing IHC and IF staining workflows.

A case study finds SARS-CoV-2 antibodies in placental cord blood after maternal vaccination.